Ambros Therapeutics agreed to merge with Werewolf in an all-stock transaction and raised $150 million, positioning the combined company to advance a Phase 3 rare disease pain program toward an approval filing. The deal follows Werewolf’s strategic search for alternatives and includes a private placement meant to fund the next regulatory and clinical steps. The combined pipeline includes Ambros’ lead candidate for a pain indication described as opioid non-responsive, and the merged company plans to push its lead asset through clinical milestones ahead of submission. This continues the broader market pattern of reverse mergers being used to secure faster access to public financing windows. For investors, the immediate question is whether the funding and combined corporate structure can sustain Phase 3 execution through key readouts and support commercialization planning if the therapy reaches approval. More broadly, the transaction illustrates how rare disease biotech can use corporate restructuring to manage cash burn while keeping late-stage timelines intact.